TY - JOUR
T1 - PCN111 health -care resource utilization in advanced melanoma:
T2 - an analysis from the Melody Observational Study
AU - Lorigan, P
AU - Maio, M
AU - Middleton, M
AU - Testori, A
AU - Bédane, C
AU - van Baardewijk, M
AU - Konto, C
AU - Dueymes, A
AU - Lebbe, C
PY - 2010/11
Y1 - 2010/11
N2 - OBJECTIVES: We conducted this study to document the health-care resource utilization associated with treatment of patients with advanced melanoma. METHODS: MELODY (Melanoma treatment patterns and outcomes among patients with unresectable stage III or stage IV disease: a retrospective longitudinal survey) is an observational study managed at 31 centers in France, Italy, and the UK. Eligible patients had attended at one of the sites with a diagnosis of unresectable stage III or IV melanoma between July 1, 2005 and June 30, 2006; data were retrieved from diagnosis (no limit date) until 2008. The primary objective was to document the first-line treatments received by patients. Secondary objectives included ascertaining health-care resource utilization related to up to three lines of treatment (anticancer and supportive care). Data were collected from patients (n = 776) using a case-report form that included information on hospitalizations, outpatient visits, hospice care, and adverse- event management (transfusions and concomitant medications including antiemetics and growth factors). Resource use data were collected from patients (n = 606) that received systemic treatment outside a clinical trial and/or supportive care. RESULTS: Twenty-nine percent (176/606) of patients required medical management for treatment-related adverse events and 32% (195/606) were hospitalized while receiving systemic treatment and/or supportive care with 25% of these having at least four hospitalizations. The median duration of hospitalization was 17 days, with 25% spending at least 29 days in hospital (may comprise multiple stays). The hospitaliza- tion rate was higher in patients receiving supportive care than those receiving anticancer treatment (86/170; 51% vs. 140/553; 25%), but median duration of hospitalization was similar (15.0 vs. 14.5 days). Results by line of anticancer therapy and supportive care will be presented. CONCLUSIONS: These results from MELODY suggest that the systemic and palliative treatments used to manage advanced melanoma are associated with considerable resource utilization, highlighting the need for more effective treatment options.
AB - OBJECTIVES: We conducted this study to document the health-care resource utilization associated with treatment of patients with advanced melanoma. METHODS: MELODY (Melanoma treatment patterns and outcomes among patients with unresectable stage III or stage IV disease: a retrospective longitudinal survey) is an observational study managed at 31 centers in France, Italy, and the UK. Eligible patients had attended at one of the sites with a diagnosis of unresectable stage III or IV melanoma between July 1, 2005 and June 30, 2006; data were retrieved from diagnosis (no limit date) until 2008. The primary objective was to document the first-line treatments received by patients. Secondary objectives included ascertaining health-care resource utilization related to up to three lines of treatment (anticancer and supportive care). Data were collected from patients (n = 776) using a case-report form that included information on hospitalizations, outpatient visits, hospice care, and adverse- event management (transfusions and concomitant medications including antiemetics and growth factors). Resource use data were collected from patients (n = 606) that received systemic treatment outside a clinical trial and/or supportive care. RESULTS: Twenty-nine percent (176/606) of patients required medical management for treatment-related adverse events and 32% (195/606) were hospitalized while receiving systemic treatment and/or supportive care with 25% of these having at least four hospitalizations. The median duration of hospitalization was 17 days, with 25% spending at least 29 days in hospital (may comprise multiple stays). The hospitaliza- tion rate was higher in patients receiving supportive care than those receiving anticancer treatment (86/170; 51% vs. 140/553; 25%), but median duration of hospitalization was similar (15.0 vs. 14.5 days). Results by line of anticancer therapy and supportive care will be presented. CONCLUSIONS: These results from MELODY suggest that the systemic and palliative treatments used to manage advanced melanoma are associated with considerable resource utilization, highlighting the need for more effective treatment options.
UR - http://www.mendeley.com/research/pcn111-healthcare-resource-utilization-advanced-melanoma-analysis-melody-observational-study
U2 - 10.1016/s1098-3015(11)72006-x
DO - 10.1016/s1098-3015(11)72006-x
M3 - Article
SN - 1098-3015
VL - 13
SP - A272
JO - Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
JF - Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
IS - 7
ER -